AbbVie Completes Acquisition of Syndesi Therapeutics, for Up To USD1 Billion
FinSMEs is the financial news site dedicated to covering venture capital, private equity, and merger and acquisition deals in real time!
Source: finsmes.com
Vives Fund News Today : Breaking News, Live Updates & Top Stories | Vimarsana
Stay updated with breaking news from Vives Fund. Get real-time updates on events, politics, business, and more. Visit us for reliable news and exclusive interviews.
Top News In Vives Fund Today - Breaking & Trending Today
AbbVie Acquires Syndesi Therapeutics, Strengthening Neuroscience Portfolio
AbbVie (NYSE: ABBV) today announced it has completed the acquisition of Syndesi Therapeutics SA, which will help to expand AbbVie's neuroscience portfolio. This acquisition gives AbbVie access to Syndesi's portfolio of novel modulators of the synaptic vesicle protein 2A (SV2A), including its lead molecule SDI-118 ...
Source: pharmiweb.com